🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 63 of 173

  1. US 10238750

    Porphyrin modified telodendrimers

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10238710

    Peptide having anti-inflammatory, osteogenic and hair growth promoting activities, and use of same

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10238674

    Bovine milk oligosaccharides

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10238655

    Dihydroindene and tetrahydronaphthalene compounds

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10238599

    Composition and method for treating congenital cytomegalovirus induced hearing loss

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10238734

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10238626

    Therapeutic compounds

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10240130

    CDNA clone-launched platform for high-yield production of inactivated zika virus

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10238770

    Reparative cell isolation and delivery

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10240157

    Diagnostic and screening methods for atopic dermatitis

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10239918

    Cahuitamycins and methods of making and using the same

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10239837

    Piperidine derivatives as HDAC1/2 inhibitors

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10239954

    Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10238698

    Biomarkers and combination therapies using oncolytic virus and immunomodulation

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10238652

    Compounds for treatment of cancer

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10233463

    Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10233438

    Engineered primate L-methioninase for therapeutic purposes

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10233240

    Methods for treating cholestatic liver fibrosis

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10233222

    Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10233235

    Modulating the alternative complement pathway

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10232059

    Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10232044

    Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10232035

    Conditionally replication deficient herpes virus and use thereof in vaccines

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10231998

    Method for chemoselection

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10231947

    Isochroman compounds and methods of use thereof

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10233420

    Methods of recellularizing a tissue or organ for improved transplantability

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10231955

    Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10231958

    Methods and compositions for enhancing chemotherapy

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10227630

    Antimicrobial agents from microbial genomes

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10227565

    Generating hepatocytes

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10226523

    Clostridium difficile vaccine and methods of use

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10226521

    Genetically modified Yersinia as vaccines against Yersinia species

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10227290

    Glycosphingolipids for use in modulating immune responses

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10226534

    Semi-solid delivery systems

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10226485

    Multipotent adult stem cells and methods for isolation

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10226516

    Process, tube and device for the preparation of wound healant composition

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10226452

    Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10227611

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10227567

    Isolation and use of solid tumor stem cells

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10226520

    Compositions and methods for enterohemorrhagic Escherichia coli (EHEC) vaccination

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10221235

    Endotrophin neutralization and use thereof

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10220117

    Methods of mammalian retinal stem cell production and applications

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10221174

    N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10220078

    Methods of using thrombin derivatives to treat medulloblastoma

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10220046

    Compositions and methods for disease treatment using nanoparticle delivered compounds

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10220070

    Alphaa-crystallin mimetic peptides and uses thereof

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10220004

    Method of controlled delivery using sub-micron-scale machines

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10220022

    Compositions and methods employing Wolbachia FtsZ as a target for Albendazole sulfone

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.